Where to Focus Next in Discovering New Antimicrobials: Practical Priorities for Research and Policy

Discovering new antimicrobials is a global priority as resistant infections rise and existing drugs lose effectiveness. This article maps where effort produces the greatest returns—scientific, clinical, and policy—and offers a practical checklist, real-world example, and actionable advice for researchers, funders, and program managers.

Why discovering new antimicrobials needs targeted focus

Current and near-term public health impact depends not only on new molecular scaffolds but also on improving the entire antimicrobial ecosystem: how compounds are discovered, validated, developed, regulated, and deployed. Key problems include long timelines, low commercial incentives, and gaps between lab discovery and clinical viability. Addressing those bottlenecks creates outsized value compared with incremental gains in any single discovery technique.

Top areas that need more focus

1. Broader, smarter screening sources and methods

Traditional soil-derived natural product screens reached diminishing returns decades ago. Diversifying sources—environmental metagenomics, microbiome-derived metabolites, synthetic biology libraries, and multi-kingdom interactions—improves hit diversity. Complementary methods such as phenotype-based high-content screens and AI-guided compound selection reduce false positives and prioritize clinically relevant activity.

2. De-risking the translational pipeline

Translational failures are common when promising hits lack ADME (absorption, distribution, metabolism, excretion) profiles or safety margins. Invest in early medicinal chemistry, standardized in vitro–in vivo correlation models, and shared preclinical infrastructure to validate efficacy and toxicity before large-scale trials. Public–private consortia and nonprofit drug development partnerships can absorb early risks.

3. Trial design and regulatory pathways for targeted agents

Narrow-spectrum agents and pathogen-specific therapies face recruitment and labeling challenges. Adaptive trial designs, platform trials, and clearer regulatory guidance enable efficient evaluation. Aligning regulatory incentives with stewardship goals prevents the paradox of introducing new drugs that rapidly drive resistance.

4. Surveillance, diagnostics, and stewardship integration

New drugs succeed only when use is controlled by rapid diagnostics and robust surveillance. Investment in point-of-care diagnostics, linked surveillance databases, and stewardship programs preserves drug utility and produces real-world effectiveness data useful to developers and payers.

5. Sustainable financing and procurement models

Current market failures mean successful antibiotics can be commercially unrewarding. Pull incentives—subscription models, milestone prizes, and long-term procurement commitments—must be paired with access and stewardship conditions to encourage development without promoting overuse.

FOCUS checklist: a practical framework for projects

Apply the FOCUS checklist on every discovery-to-deployment pathway:

• F — Find: diversify sample sources, use orthogonal screening to reduce artifacts.
• O — Optimize: early medicinal chemistry and ADME/tox screens to raise developability.
• C — Confirm: standardized in vitro and in vivo models and reproducible potency measures.
• U — Use-readiness: diagnostics compatibility, stewardship plans, and narrow-spectrum prioritization.
• S — Sustain: plan financing/market entry strategies that balance access and incentives.

Practical tips for teams working on discovering new antimicrobials

• Integrate diagnostics early: design compounds with companion diagnostic strategies in mind to support targeted use and easier trials.
• Share preclinical data in consortia: pooled toxicology and PK/PD (pharmacokinetic/pharmacodynamic) datasets reduce duplicated effort and accelerate go/no-go decisions.
• Use adaptive, pathogen-focused trial designs: reduce sample size and time to signal for rare or drug-resistant infections.
• Plan stewardship and access simultaneously: procurement contracts should include monitoring and prescribing guidelines.

Trade-offs and common mistakes

Focusing on novel mechanisms of action yields scientific novelty but increases clinical and development risk; balancing novelty with known developability traits is often wiser. Common mistakes include over-reliance on single screening assays, ignoring early ADME/tox profiles, and treating market access as a later step rather than a core design constraint. Overemphasis on broad-spectrum activity can undermine stewardship objectives and accelerate resistance.

Real-world example

Scenario: A small biotech discovers a peptide with strong activity against carbapenem-resistant Enterobacterales from soil metagenomic libraries. Applying the FOCUS checklist leads to early medicinal chemistry to improve stability (Optimize), parallel development of a rapid diagnostic test for target strains (Use-readiness), and collaboration with a nonprofit to secure pull-funding for Phase II trials (Sustain). Combined early actions reduced the timeline to a pivotal trial and ensured the drug would be deployed with stewardship safeguards.

Core cluster questions for follow-up articles and internal linking

• What are high-priority methods for prioritizing hits in antimicrobial screens?
• How can adaptive clinical trial designs accelerate antibiotic approval?
• Which financing models best balance access and developer incentives for new antimicrobials?
• What surveillance architectures are needed to monitor resistance to novel agents?
• How do companion diagnostics change the value proposition for narrow-spectrum drugs?

Standards, organizations, and best-practice resources

Aligning discovery and development work with recognized standards improves credibility and uptake. Relevant organizations include the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). For global best practices on antimicrobial resistance and policy guidance, see the World Health Organization: Antimicrobial resistance (WHO).

Implementation roadmap (6–18 months)

• Months 0–3: Apply FOCUS checklist to candidate programs; audit screening diversity and early ADME plans.
• Months 3–9: Build partnerships for shared preclinical studies and begin diagnostic co-development for prioritized candidates.
• Months 9–18: Prepare adaptive trial protocols and secure funding commitments tied to stewardship and access conditions.

Monitoring success

Key indicators: number of candidates reaching IND-enabling studies with companion diagnostics, time from hit to Phase I reduced, and existence of procurement commitments with stewardship clauses. Surveillance data should be used to report real-world effectiveness and early resistance signals.

How can researchers accelerate discovering new antimicrobials?

Accelerate progress by diversifying discovery sources, integrating early developability assessments, partnering for shared preclinical infrastructure, and aligning trial design and diagnostic development to shorten translational timelines.

What are common pitfalls when prioritizing antimicrobial leads?

Common pitfalls include relying on a single assay, underestimating ADME/tox liabilities, ignoring diagnostic compatibility, and delaying planning for stewardship and market access.

How do surveillance and diagnostics affect the value of new drugs?

Surveillance and rapid diagnostics enable targeted use, preserve drug effectiveness, and provide post-marketing data that increases payer and regulatory confidence, raising the real-world value of new antimicrobials.

Which incentives best support late-stage antibiotic development?

Pull incentives such as subscription payments, milestone prizes, and advance market commitments have shown promise when combined with access and stewardship conditions to prevent misuse.

How can funders measure ROI in antimicrobial discovery programs?

Measure ROI through go/no-go rate improvements, time-to-proof metrics, number of candidates reaching clinical milestones, and public-health outcomes such as reductions in resistant infections in covered settings.